Nanobiotix (NBTX) Stock Price, News & Analysis

Company Overview

Nanobiotix is a French biotechnology company developing nanoparticle-based treatments for cancer. Founded in 2003, the company focuses on using nanomedicine to enhance the effects of established cancer therapies, particularly radiation therapy.

Its lead product candidate, NBTXR3, is made from hafnium oxide nanoparticles and is designed to be injected directly into a tumor. When exposed to radiation, the particles are intended to increase damage to cancer cells while limiting the effect on surrounding healthy tissue. Nanobiotix is studying NBTXR3 in clinical programs for several cancer types, including head and neck cancers.

NBTXR3 has received CE marking in Europe for use with radiation therapy in adults with locally advanced soft tissue sarcoma. Nanobiotix is headquartered in France and conducts development activities across international markets.

Key Stats

• Today's Range: $30.32 to $32.35
• 50-Day Range: $21.08 to $38.80
• 52-Week Range: $19.14 to $57.14
• Volume: 93,105 shs
• Average Volume: 151,759 shs
• Market Capitalization: $1.56 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $46.67
• Consensus Rating: Moderate Buy

Nanobiotix Stock Analysis - MarketRank™

Nanobiotix scored higher than 68% of companies evaluated by MarketBeat, and ranked 254th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Nanobiotix has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Nanobiotix has a consensus price target of $46.67, representing about 52.2% upside from its current price of $30.66.

Amount of Analyst Coverage

Nanobiotix has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Nanobiotix are expected to grow in the coming year, from ($0.62) to $0.16 per share.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.35% of the float of Nanobiotix has been sold short.

Short Interest Ratio / Days to Cover

Nanobiotix has a short interest ratio ("days to cover") of 1.39, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nanobiotix has recently decreased by 13.45%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nanobiotix does not currently pay a dividend.

Dividend Growth

Nanobiotix does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.61

News Sentiment

Nanobiotix has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Nanobiotix this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for NBTX on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nanobiotix insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.45% of the stock of Nanobiotix is held by insiders.

Percentage Held by Institutions

38.81% of the stock of Nanobiotix is held by institutions.

Company Calendar

• Today: 11/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NBTX
• CIK: 1760854
• Web: www.nanobiotix.com
• Phone: 33-1-40-26-04-70
• Fax: N/A
• Employees: 97
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Nanobiotix: $46.67
• High Price Target: $64.00
• Low Price Target: $30.00
• Potential Upside/Downside: +52.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.44
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $36.87 million
• Price / Sales: 42.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.97) per share
• Price / Book: -15.56

Miscellaneous

• Outstanding Shares: 50,970,000
• Free Float: 49,210,000
• Market Cap: $1.56 billion
• Optionable: Optionable
• Beta: 0.89